Long-lasting remission in de novo breast myeloid sarcoma treated with decitabine and radiotherapy

Research output: Contribution to journalArticle

Abstract

Myeloid sarcoma (MS) represents a rare disease with an adverse clinical outcome for patients not candidate to acute myeloid leukemia (AML)-like chemotherapies. Here we present the case of an elderly patient affected by a bilateral breast localization of MS treated with the hypomethylating agent decitabine associated to radiotherapy. The association of the two treatment modalities has allowed an optimal and long-lasting disease control.

Original languageEnglish
Article number84
JournalDiagnostics
Volume9
Issue number3
DOIs
Publication statusPublished - Sep 1 2019

    Fingerprint

Keywords

  • Acute myeloid
  • Breast
  • Decitabine
  • Extramedullary
  • Leukemia
  • Myeloid
  • Sarcoma

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this